K
Kayleigh Marx
Researcher at University of Texas MD Anderson Cancer Center
Publications - 23
Citations - 659
Kayleigh Marx is an academic researcher from University of Texas MD Anderson Cancer Center. The author has contributed to research in topics: Myeloid leukemia & Medicine. The author has an hindex of 8, co-authored 18 publications receiving 401 citations. Previous affiliations of Kayleigh Marx include University of Kentucky.
Papers
More filters
Journal ArticleDOI
Clinical experience with the BCL2‐inhibitor venetoclax in combination therapy for relapsed and refractory acute myeloid leukemia and related myeloid malignancies
Courtney D. DiNardo,Caitlin R. Rausch,Christopher B. Benton,Tapan M. Kadia,Nitin Jain,Naveen Pemmaraju,Naval Daver,Wendy Covert,Kayleigh Marx,Morgan Mace,Elias Jabbour,Jorge E. Cortes,Guillermo Garcia-Manero,Farhad Ravandi,Kapil N. Bhalla,Hagop M. Kantarjian,Marina Konopleva +16 more
TL;DR: Venetoclax (VEN), a selective BCL2 inhibitor, has single‐agent activity in relapsed and refractory (R/R) acute myeloid leukemia (AML), and efficacy in lower intensity combinations for treatment‐naïve elderly AML patients.
Journal ArticleDOI
Isavuconazole: Pharmacology, Pharmacodynamics, and Current Clinical Experience with a New Triazole Antifungal Agent
TL;DR: Clinical experience thus far has revealed isavuconazole to be associated with fewer toxicities than voriconazole, even when administered without therapeutic drug monitoring, which will likely make isavunazole a welcome addition to the triazole class of antifungals.
Journal ArticleDOI
Early experience with tedizolid: clinical efficacy, pharmacodynamics, and resistance.
TL;DR: Although the clinical experience with tedizolid remains limited, early data suggest a potential role in the treatment of serious infections due to multidrug‐resistant gram‐positive pathogens.
Journal ArticleDOI
Isavuconazole as Primary Antifungal Prophylaxis in Patients With Acute Myeloid Leukemia or Myelodysplastic Syndrome: An Open-label, Prospective, Phase 2 Study.
Prithviraj Bose,David McCue,Sebastian Wurster,Nathan P. Wiederhold,Marina Konopleva,Tapan M. Kadia,Gautam Borthakur,Farhad Ravandi,Lucia Masarova,Koichi Takahashi,Zeev Estrov,Musa Yilmaz,Naval Daver,Naveen Pemmaraju,Kiran Naqvi,Caitlin R. Rausch,Kayleigh Marx,Wei Qiao,Xuelin Huang,Carol Bivins,Sherry Pierce,Hagop M. Kantarjian,Dimitrios P. Kontoyiannis +22 more
TL;DR: ISAV is a safe and effective alternative for PAP in patients with newly diagnosed AML/MDS undergoing RIC in the era of recently approved or emerging small-molecule anti-leukemia therapies.
Journal ArticleDOI
Venetoclax and BCR-ABL Tyrosine Kinase Inhibitor Combinations: Outcome in Patients with Philadelphia Chromosome-Positive Advanced Myeloid Leukemias.
Abhishek Maiti,Miguel Franquiz,Farhad Ravandi,Jorge E. Cortes,Elias Jabbour,Koji Sasaki,Kayleigh Marx,Naval Daver,Tapan M. Kadia,Marina Konopleva,Lucia Masarova,Gautam Borthakur,Courtney D. DiNardo,Kiran Naqvi,Sherry Pierce,Hagop M. Kantarjian,Nicholas J. Short +16 more
TL;DR: Combination therapy of venetoclax with TKI-based regimens shows encouraging activity in very heavily pretreated, advanced Ph+ leukemias, particularly CML-MBP.